Compare PTON & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTON | KLRA |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2019 | 2026 |
| Metric | PTON | KLRA |
|---|---|---|
| Price | $4.95 | $13.94 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $7.89 | N/A |
| AVG Volume (30 Days) | ★ 7.1M | 745.2K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.67 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.44 | N/A |
| P/E Ratio | $36.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.65 | $14.76 |
| 52 Week High | $9.20 | $23.82 |
| Indicator | PTON | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 35.61 |
| Support Level | $4.44 | N/A |
| Resistance Level | $6.00 | $19.02 |
| Average True Range (ATR) | 0.17 | 1.22 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 0.77 | 7.03 |
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Products derive revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.